STAT

For tiny biotechs, J.P. Morgan is a big opportunity — and a big cost

The biggest names in biotech descend on San Francisco for #JPM19. Is it worth it for some of the smallest names in the industry?

For four days in January, the biggest names in biotech descend on the J.P. Morgan Healthcare Conference in San Francisco to unveil splashy merger and acquisition announcements, offer out-of-the-box meditations on drug pricing, and schmooze.

But some of the smallest and newest names in biotech are there, too, trying not to get lost in the noise.

These companies aren’t making headline-grabbing presentations or hosting big parties. But the conference gives tiny startups and even small- and mid-size public companies a pivotal — and unmissable — opportunity, executives at three different companies told STAT. For them, the conference is their chance to

You’re reading a preview, subscribe to read more.

More from STAT

STAT2 min read
STAT+: Pharmalittle: We’re Reading About Abortion Pill Arguments, A Merck Drug Approval, And More
U.S. Supreme Court justices focused on plaintiffs' right to sue the FDA to reinstate restrictions on a commonly used abortion pill, suggesting they are unlikely to restrict access.
STAT1 min read
STAT+: New Gene Therapy, To Be Priced At $4.25 Million, Has Already Transformed Children’s Lives
The world's most expensive treatment offers a near-cure for young children and redemption for its developer, but steep challenges still loom.
STAT2 min read
STAT+: Pharmalittle: We’re Reading About CAR-T Drugs For Myeloma, CVS Rebate Credits, And More
A FDA panel voted in favor of expanding use of CAR-T therapy in multiple myeloma, despite concerns about side effects.

Related Books & Audiobooks